This study H0P -MC-NP05 ([STUDY_ID_REMOVED] ) is a sub -study of Master Protocol H0P -MC-
CPMP ([STUDY_ID_REMOVED])  
 
Protocol : H0P-MC-NP05 (a) 
 
Randomized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for the 
Treatment of Diabetic Peripheral Neuropathic Pain   
 
[STUDY_ID_REMOVED]  
 
Approval Date: 13-Oct-2022  
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
1 Title Page  
Confidential Information  
The information contained in this document is confidential and is intended for the use of clinical investigators. It is the p roperty of 
Eli Lilly and Company or its subsidiaries and should not be copi[INVESTIGATOR_51937]3857210 , unless such persons are bound by a confidentiality agreement with Eli Lilly and Company or its 
subsidiaries.  
 
Note to Regulatory Authorities:  This document may contain protected personal data and/or commercially confidenti al information 
exempt from public disclosure. Eli Lilly and Company requests consultation regarding release/redaction prior to any public re lease. 
In the [LOCATION_002], this document is subject to Freedom of Information Act (FOIA) Exemption 4 and may not b e reproduced or 
otherwise disseminated without the written approval of Eli Lilly and Company or its subsidiaries . 
Master Protocol Title:  A Master Protocol for Randomized, Placebo -Controlled, Phase 2 
Clinical Trials of Multiple Interventions for the Treatme nt of Chronic Pain  
Master Protocol Number: H0P-MC-CPMP  
ISA Title:  Randomized, Placebo -Controlled, Phase 2 Clinical Trial to Evaluate LY3857210 for 
the Treatment of Diabetic Peripheral Neuropathic Pain  
ISA Number: H0P-MC-NP05  
Amendment Number:  a 
Compound: LY3857210  
Brief Title: Phase 2 Clinical Trial to Evaluate LY3857210 for the Treatment of Diabetic 
Peripheral Neuropathic Pain  
Study Phase: 2 
Acronym : NP05   
Sponsor Name: [CONTACT_11028]: Indianapolis, Indiana , [LOCATION_003] [ZIP_CODE]  
Regulatory Agency Identifier Number s: 
LY3857210 IND: 156411  
Master Protocol IND: 144915  
Approval Date: Protocol  H0P-MC-NP05 Amendment (a) Electronically  Signed 
and Approved  by [CONTACT_141693].   
 
Document ID:  VV-CLIN -[ADDRESS_629864] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629865] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
3 Protocol Amendment Summary of Changes Table  
 
DOCUMENT HISTORY  
Document  Date  
Original Protocol  25-Aug-2022  
Amendment a  
Overall Rationale for the Amendment:  
This amendment adds additional physical exam ination s and exclusion criteria to address 
regulatory feedback.  
Section # and 
Name  [CONTACT_11029]  
1.3. Schedule 
of Activities  Added Physical examinations at Visits 5 and 7.   
Added note, “ Complete physical examination , 
including targeted examination  specified 
below, should be performed at V3 and V801 or 
ED. Targeted physical examination  for skin, 
gastrointestinal tract, mammary g land in 
males , and lymph nodes should also be 
performed at V5 and V7. ” Per regulatory feedback.  
 Removed text in note s for vital signs, “…and 
prior to PK sample collection.”  Editorial correction.  
5.2. 
Exclusion 
Criteria  Modified criterion [3085], “have completed  
participated in …”. Clarification.  
 
8.2.1. 
Physical 
Examinations  Added, “ Complete physical examination , 
including targeted examination  specified 
below, should be performed at V3 and Visit 
[ADDRESS_629866], mammary gland in 
males , and lymph nodes will also be performed 
at Visits V5  and V7 as described in the SoA. 
Any clinically significant abnormal physical 
examination findings will be reported as AEs. ” Per regulatory feedback.  
Approved on [ADDRESS_629867] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
4 Section # and 
Name  [CONTACT_489931], “…to physical examinations 
(described in Master Protocol CPMP )…” Editorial.  
 
Approved on [ADDRESS_629868] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
5 Table of Contents  
1. Protocol Summary  ................................ ................................ ................................ .......... 8 
1.1. Synopsis  ................................ ................................ ................................ ............................ 8 
1.2. Schema  ................................ ................................ ................................ ............................ 10 
1.3. Schedule of Activities (SoA)  ................................ ................................ .......................... 11 
2. Introduction  ................................ ................................ ................................ ................... 15 
2.1. Study R ationale  ................................ ................................ ................................ ............... 15 
2.2. Background  ................................ ................................ ................................ ..................... 15 
2.3. Benefit/Risk Assessment  ................................ ................................ ................................ 15 
2.3.1.  Risk Assessment  ................................ ................................ ................................ ............. 15 
2.3.2.  Benefit Assessment  ................................ ................................ ................................ ......... 16 
2.3.3.  Overall Benefit Risk Conclusion  ................................ ................................ .................... 16 
3. Objectives, Endpoints, and Estimands  ................................ ................................ .......17 
4. Study Design  ................................ ................................ ................................ .................. 18 
4.1. Overall  Design  ................................ ................................ ................................ ................ 18 
4.2. Scientific Rationale for Study Design  ................................ ................................ ............ 18 
4.3. Justification for Dose  ................................ ................................ ................................ ......18 
4.4. End of Study Definition  ................................ ................................ ................................ ..19 
5. Study Population  ................................ ................................ ................................ ........... 20 
5.1. Inclusion Criteria  ................................ ................................ ................................ ............ 20 
5.2. Exclusion Criteria  ................................ ................................ ................................ ........... 20 
5.3. Lifestyle Considerations  ................................ ................................ ................................ .21 
5.3.1.  Substance Use  ................................ ................................ ................................ ................. 21 
5.4. Screen Failures  ................................ ................................ ................................ ................ 21 
5.5. Criteria for Temporarily Delaying Enrollment, Randomization, 
or Administration of Study Intervention of a Par ticipant  ................................ ............... 21 
6. Study Intervention(s) and Concomitant Therapy  ................................ ..................... 22 
6.1. Study Intervention(s) Administered ................................ ................................ ................ 22 
6.2. Preparation, Handling, Storage, and Accountability  ................................ ...................... 22 
6.3. Measures to Minimize Bias: Randomization and Blinding  ................................ ............ 22 
6.3.1.  Stratification  ................................ ................................ ................................ .................... 22 
6.4. Study Intervention Compliance  ................................ ................................ ...................... 22 
6.5. Dose Modification  ................................ ................................ ................................ .......... 22 
6.6. Continued Access to Study Intervention after the End of the 
Study  ................................ ................................ ................................ ............................... 22 
6.7. Treatment of Overdose  ................................ ................................ ................................ ...23 
6.8. Concomitant Therapy  ................................ ................................ ................................ .....23 
6.8.1.  Permitted Medications  ................................ ................................ ................................ ....23 
6.8.2.  Prohibited Medications  ................................ ................................ ................................ ...23 
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal ................................ ................................ ........................ [ADDRESS_629869] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
6 7.1.2.  Hypersensitivity  ................................ ................................ ................................ .............. 25 
7.2. Participant Discontinuation/Withdrawal from the Study  ................................ ................ [ADDRESS_629870]  ................................ ................................ ................. 28 
8.4. Pharmacokinetics  ................................ ................................ ................................ ............ 29 
8.5. Pharmacodynamics  ................................ ................................ ................................ ......... 29 
9. Statistical Considerations  ................................ ................................ ............................. 30 
9.1. Statistical Hypotheses  ................................ ................................ ................................ .....30 
9.2. Analyses Sets  ................................ ................................ ................................ .................. 30 
9.3. Statistical Analyses  ................................ ................................ ................................ ......... 30 
9.3.1.  General Considerations  ................................ ................................ ................................ ...30 
9.3.2.  Tertiary Analysis  ................................ ................................ ................................ ............. 30 
9.3.3.  Safety Analyses  ................................ ................................ ................................ ............... 30 
9.3.4.  Exploratory Pharmacokinetic Analyses  ................................ ................................ .......... 31 
9.4. Interim Analysis  ................................ ................................ ................................ .............. 31 
9.5. Sample Size Determination  ................................ ................................ ............................ 31 
10. Supporting Documentation and Operational Considerations  ................................ ..32 
10.1.  Appe ndix 1: Regulatory, Ethical, and Study Oversight 
Considerations  ................................ ................................ ................................ ................ 32 
10.2.  Appendix 2: Clinical Laboratory Tests  ................................ ................................ ........... 33 
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic 
Hypersensitivity Event  ................................ ................................ ................................ ....33 
10.3.  Appendix 3: Adverse Events and Serious Adverse Events: 
Definitions and Procedures for Recording, Evaluating, Follow -
up, and Reporting  ................................ ................................ ................................ ............ 35 
10.4.  Appendix 4: Contraceptive and Barrier Guidance  ................................ .......................... 36 
10.4.1.  Definitions ................................ ................................ ................................ ....................... 36 
10.4.2.  Contraception Guidance ................................ ................................ ................................ ..37 
10.5.  Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments  ................................ ................................ ................................ .................... [ADDRESS_629871] 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
7 10.6.  Appendix 6: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  ................................ ................................ ............................. 40 
10.7.  Appendix 7: Abbreviations and Definitions  ................................ ................................ ...[ADDRESS_629872] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
8 1. Protocol Summary  
1.1. Synopsis  
ISA Title:   
Randomized , Placebo -Controlled , Phase 2 Clinical Trial to Evaluate  LY3857210 for the 
Treatment  of Diabetic Peripheral Neuropathic Pain 
Brief Title:  Phase  2 Clinical Trial to Evaluate LY3857210 for the Treatment of Diabetic 
Peripheral Neuropathic Pain  
Regulatory Agency Identifier Numbers:   
LY3857210 IND: 156411  
Master Protocol IND: 144915  
Rationale : 
The purpose of this study is to test whether LY3857210 is efficacious in decreasing diabetic 
peripheral neuropathic pain (DPNP). LY3 [ADDRESS_629873] of the 
P2X7 receptor, an adenosine triphosphate ligand -gated ion channel known to be involved in 
neuroinflammation and pai n.  
Data will be collected to assess the safety and tolerability of LY3857210 in this study population. 
The p harmacokinetic s of LY3857210  will also be explored. The totality of data from this proof -
of-concept study will assess the benefits and risks associ ated with LY3857210 and inform 
decisions for the clinical development of LY3857210.  
Objectives , Endpoint s, and Estimands:  
The primary and secondary objectives and endpoints are stated in the Master Protocol H0P -MC-
CPMP (CPMP) and the DPNP disease -state addendum (DSA; H0P -MC-CPMP[3]).  
Overall Design : 
This is a 10-week  Phase 2, randomized, double -blind, placebo -controlled stud y that will compare 
LY3857210 versus placebo in participants with DPNP.  
Study Population:  
In addition to inclusion and exclusion criteria described in Master Protocol CPMP and DSA 
CPMP(3), individuals may not take part in the study if they  have 
 an eGFR of less than 30 m L/min/1.[ADDRESS_629874] 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
9 Number of Participants:  
Up to approximately 125 participants will be randomly assigned to study intervention with the 
assumption that 20% of the participants will drop out prior to the end of the double -blind 
treatment period.  
Intervention Groups and Duration:  
This double -blind study includes an 8 -week treatment period with a  2-week follow -up visit off 
treatment.  
Intervention Name  [CONTACT_36940]3857210  Placebo  
Dosage Level(s)  45 mg daily  Not applicable  
Route of Administration  
and Duration  PO PO 
Abbreviation: PO  = by [CONTACT_1966].  
Ethical Considerations of Benefit/Risk:  
Taking into account the measures taken to minimize risk to participants participating in this 
study, the potential risks identified in association with LY3857210 are justified by [CONTACT_489923].  
Data Monitoring Committee: Yes 
Safety reviews are covered by [CONTACT_489924] (CPMP).  
 
Approved on [ADDRESS_629875] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
10 1.2. Schema  
 
 
Abbreviations: PDEP  = preliminary data entry period; V  = visit.  
a  Medication washout and PDEP begins.  
b  Randomization to either LY3857210 or placebo.  
 
 
Approved on [ADDRESS_629876] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
11 1.3. Schedule of Activities  (SoA)  
This SoA shows visits and procedures unique to the intervention -specific appendix (ISA) H0P -MC-NP05 for LY3857210. Please refer 
to Master Protocol CPMP and the DPNP DSA CPMP(3) SoAs for additional information.  
  Screening  Randomiza
tion to ISA  Double -Blind  
Treatment   F/U Notes  
 V1 V2 V3 V4 V5 V6 V7 ED V801    
Study Week  Up to -[ADDRESS_629877] participants  0 2 4 6 8  +2   
Visit Window (days)     ±3  ±3  
Confirm ISA inclusion 
and exclusion criteria  X X X        
Physical examination    X   X   X X X Physical exam ination  (see Section 
8.2.1 ). Complete physical exam ination , 
including targeted exam ination  
specified below, should be performed at 
V3 and V801 or ED. Targeted physical  
exam ination  for skin, gastrointestinal 
tract, mammary gland in males , and 
lymph nodes should also be performed 
at V5 and V7.  
Neurological assessment    X X X X X X X See Section 8.2.1 . 
Prespecified DPNP 
medical history    X       Includes diagnosis  and symptom onset 
date.  
Vital signs    X X X X X X X At V3, vitals should be taken predose.  
Pulse rate, respi[INVESTIGATOR_697], blood 
pressure, and temperature taken with 
participant in a sitting position.  
Concomitant medication          X See footnote a.  
AE         X See footnote a.  
ECG  (single)       X   X X X  
Approved on [ADDRESS_629878] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
12   Screening  Randomiza
tion to ISA  Double -Blind  
Treatment   F/U Notes  
 V1 V2 V3 V4 V5 V6 V7 ED V801    
Study Week  Up to -[ADDRESS_629879] participants  0 2 4 6 8  +2   
Visit Window (days)     ±3  ±3  
Placebo response video 
training (participant)   X        Should view at the beginning of V2. 
Study intervention  
administration    X X X X     See Section 6.1. Participant should be 
instructed NOT to take study 
intervention on the day of V7 . 
Dispense study 
intervention to participant    X X X X     
Participant returns unused 
study intervention     X X X X X  Participant to bring study intervention 
to every visit.  
Intervention compliance      X X X X X   
Scales, Questionnaires, and Outcome Measures  
 
C-SSRS Since Last Visit          X See footnote a.  
Self-Harm Supplement 
form          X See footnote a.  
Self-Harm Follow -Up 
form          X See footnote a.  
Complete [ADDRESS_629880] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
13   Screening  Randomiza
tion to ISA  Double -Blind  
Treatment   F/U Notes  
 V1 V2 V3 V4 V5 V6 V7 ED V801    
Study Week  Up to -[ADDRESS_629881] participants  0 2 4 6 8  +2   
Visit Window (days)     ±3  ±3  
PGI         X See footnote a.  
Clinical Laboratory Tests and Sample Collection  
Hematology     X X X X  X   
Chemistry     X X X X  X   
Lipid panel     X X X X  X   
Urinalysis            X  X   
Urine pregnancy    X X X X X X  For all WOCBP at V3: collect sample 
within [ADDRESS_629882] 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
14   Screening  Randomiza
tion to ISA  Double -Blind  
Treatment   F/U Notes  
 V1 V2 V3 V4 V5 V6 V7 ED V801    
Study Week  Up to -[ADDRESS_629883] participants  0 2 4 6 8  +2   
Visit Window (days)     ±3  ±3  
Participant Devices  
Abbreviations: AE = adverse event; ; DPMP = diabetic peripheral neuropathic pain; ECG = electrocardiogram; ED = early 
discontinuation; F/U = follow -up; HbA1c = hemoglobin A1c; ISA  = intervention -specific appendix; MoO = Manual of Operations; NRS = numeric rating 
scale; PGI = patient’s global impression of change; PK = pharmacokine tic; V = visit; WOCBP = women of childbearing potential.  
a Collect in addition to schedule described in  Master Protocol  CPMP.  
 
Approved on [ADDRESS_629884] 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
15 2. Introduction  
This ISA , H0P-MC-NP05 (NP05) is an appendix to Master Protocol H0P-MC-CPMP (CPMP) 
and contains unique study elements specific for LY3857210. The master protocol contains the 
overarching study elements that govern the DPNP DSA CPMP(3) and this ISA NP05.  
2.1. Study Rationale  
The purpose of this study is to test whether LY38 [ZIP_CODE] is efficacious in decreasing DPNP. Data 
will be collected to assess the safety and tolerability of LY3857210  in this study population. The 
PK of LY3857210 will also be explored. The totality of data from this POC study will assess the 
benefits and risks associated with LY3857210  and inform decisions for the clinical development 
of LY3857210.  
2.2. Background  
P2X7 is an adenosine triphosphate (ATP) ligand -gated ion  channel that when activated results in 
Ca2+ influx, and cellular activation ( for example,  caspase 1). For a recent review article, see 
Zhang et al. 2020. Stimulation of P2X7 plays a key role in the cross talk of the glial cells and 
neurons at an over -active synapse and in neuroinflammatory conditions (Curr ò et al. 2020) . 
Thus, inhibition of the P2X7 receptor found on glial cells in the brain and spi[INVESTIGATOR_454462].  
LY3857210 is an orally administered small -molecul e receptor antagonist of the P2X7 receptor .  
2.3. Benefit/Risk Assess ment  
More detailed information about the known and expected benefits and risks and reasonably 
expected  AEs of LY3857210 may be found in the IB.  
2.3.1.  Risk Assessment  
Study intervention  
Toxicology studies and NOAEL exposure  
Based on the observed convulsion in the 3 -month dog toxicology study (reported in 1 dog) as 
well as convulsion noted in the rat in vivo micronucleus study  (reported in 1 rat) , a [ADDRESS_629885] 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
16 exposure multiple based on the observed AUC and C max associated with the NOEL for 
convulsions in dog (the most sensitive species) will be maintained in th is study  
  
In addition,  neurological examination will be conducted at regular intervals during the study 
period and  AEs related to CNS signs and symptoms will be collected during the study. 
Participants with a history of seizures will be excluded from the study.  
Potential drug -drug interactions  
Clinical drug -drug interaction studies have not been conducted with LY3857210 . Based on 
current in vitro data, LY3857210 is a potential inducer of CYP3A4, CYP1A2, CYP 2B6, and 
CYP 2C8. To mitigate risk,  participants taking  sensitive substrates with a narrow therapeutic 
index are excluded. See Section 5.2 for exclusion criteria  and r efer to IB for more information . 
Information on AEs expected to be related to the study intervention  may be found in the IB . 
Information on SAEs that are expected in the study population independent of drug exposure will 
be assessed by [CONTACT_240209], periodically during the course of the study, and may be 
found in the IB . 
2.3.2.  Benefit Assessment  
Potential benefits for the study participants include :  
 information obtained from study -related medical procedures  
o physical examinations  
o laboratory tests , and   
o ECGs .  
 detailed evaluations of diabetic nerve pain , and   
 questionnaires that may improve participants understanding t heir own condition.  
As part of Study CPMP, participants in this ISA will report their experience using standard tools 
that may contribute to the assessment of novel treatments for DPNP. In addition, data collected 
from this study may also improve our unde rstanding of DPNP pathogenesis. Both of which may 
lead to the development of new treatment with improved safety and efficacy profile compared to 
standard of care.  
2.3.3.  Overall Benefit Risk Conclusion  
Taking into account the measures taken to minimize risk to p articipants participating in this 
study, the potential risks identified in association with LY3857210 are justified by [CONTACT_489925].  
Approved on [ADDRESS_629886] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
17 3. Objectives , Endpoints , and Estimands  
The CPMP Master Protocol an d DPNP DSA CPMP(3) include objectives and endpoints 
applicable for this study. This table describes objectives and endpoints specific for LY3857210.  
Approved on [ADDRESS_629887] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
18 4. Study Design  
4.1. Overall  Design  
Master Protocol CPMP describes the overall study design and study design rationale. This 
section describes visits and overall procedures unique to ISA NP05 for LY3857210 in addition to 
the procedures outlined in CPMP and CPMP(3) .  
Double -blind treatment period (Visits 3 t hrough 7)  
Each visit is an outpatient visit.  
At Visit 3 , 
 participants are randomly assigned  to LY3857210  or placebo  
 the site completes the NP05 baseline procedures and  sample collection (excluding PK ) 
prior to  study intervention  
 the site collects particip ants’ vitals predose  
 participants receive their oral study intervention  
 the site completes PK sample collection, and  
 the site instructs participants to continue with study restrictions and NRS diary entries 
before their visit discharge.  
At Visits 4 throu gh 7, 
 the site reviews available safety data and sample collection  
 participants continue oral study intervention (not applicable for V isit 7) and bring all 
study intervention bottles to each visit  
 the site completes all sample collection and safety monitoring noted in the SoAs, and  
 the site instructs participants to continue with study restrictions , NRS diary entries , and 
wearing of  before their visit discharge.  
Double -blind post-treatment follow -up period (Visit 801)  
 Participants must complete [ADDRESS_629888] -treatment follow -up visit for safety and efficacy 
assessment at Visit 801 according to the SoA  
 the site schedules Visit 801 approximately 2 weeks after Visit 7  or ED Visit , and  
 at Visit 801, participants return the device s  
4.2. Scientific Rationale for Study Design  
Master Protocol CPMP describes the overall study design rationale.  
4.3. Justification for Dose  
Approved on [ADDRESS_629889] 2022 GMT
CCI
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629890] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
20 5. Study Population  
Master Protocol CPMP and DPNP DSA CPMP(3) provide eligibility criteria that must be 
followed for this study. LY 3857210 -specific inclusion and exclusion criteria are listed here.  
5.1. Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
Sex and contraceptive/ barrier requirements  
[3075]  Males and females may participate in this trial.  
No male contraception is required except in compliance with specific local 
government study requirements.  
WOCBP and WNOCBP may participate in this trial. See Section  10.4 for definitions 
and additional requirements related to contraception.  
Contraceptive use by [CONTACT_489926].    
5.2. Exclusion Criteria   
Participants are excluded from the study if any of the following criteria apply:  
[3077]  Have an eGFR of <30 m L/min/1.73 m , based on the Chronic Kidney Disease 
Epi[INVESTIGATOR_10444] (CKD -EPI) formula at Visit 1 or Visit 2.  
[3078]  Have known allergies to LY3857210, related compounds or any components of the 
formulation, or history of significant atopy.  
[3079]  Women wh o are pregnant or breastfeeding.  
Approved on [ADDRESS_629891] 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629892] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
22 6. Study Intervention (s) and Concomitant Therapy  
6.1. Study Intervention(s) Administered  
This table lists the interventions used in this clinical study.  
Intervention Name  [CONTACT_36940]3857210  Placebo  
Dosage Level(s)  45 mg daily  N/A 
Route of Administration  PO PO 
Abbreviations: N/A = not applicable; PO = by [CONTACT_1966] . 
Packaging and labeling  
Study interventions will be supplied by [CONTACT_489927]. Study interventions will be labeled as appropriate for country 
requireme nts. 
6.2. Preparation , Handling , Storage , and Accountability  
Preparation, handling, storage, and accountability are described in Master Protocol CPMP.  
6.3. Measures to Minimize Bias: Randomization and Blinding  
Randomization and blinding are described in Master Protocol CPMP.  
6.3.1.  Stratification  
There are no additional stratification factors for this study.  
6.4. Study Intervention Compliance  
When participants self -administer study intervention(s) at home, compliance with study 
intervention will be assessed at each visit. Compliance will be assessed by [CONTACT_489928]. A record of the 
number of study intervention capsules dispensed to and taken by [CONTACT_21444]. Intervention start and 
stop dates will also be recorded in the CRF.  
6.5. Dose  Modification  
Dose modification is not permitted.  
6.6. Continued Access to Study Intervention after the End of the Study  
Not applicable.  
Approved on [ADDRESS_629893] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629894] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
24 7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  
7.1. Discontinuation of Study Intervention  
Master Protocol CPMP and CPMP(3) DSA provide the reasons and procedures for 
discontinuation of intervention and participant discontinuation that must be followed for this 
study.  
7.1.1.  Liver Chemistry Stoppi[INVESTIGATOR_489921] (see Section 
8.2.5 of Master Protocol CPMP) if 1 or more of these conditions occur:  
Elevation  Exception  
ALT or AST >8x ULN   
ALT or AST >5x ULN for more than [ADDRESS_629895] >3x ULN and either TBL >2x ULN or INR >1.5  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL, 
then doubling of direct bilirubin should be 
used for drug interruption decisions rathe r 
than TBL>2x ULN  
ALT or AST >3x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
ALP >3x ULN, when the source of increased ALP is the liver   
ALP >2.5x ULN and TBL > [ADDRESS_629896]  For participants with Gilbert’s syndrome:  
If baseline direct bilirubin is >0.5 mg/dL , 
then doubling of direct bilirubin should be 
used for drug interruption decisions rather 
than TBL>2x ULN  
ALP >2.5x ULN with the appearance of fatigue, nausea, 
vomiting, right upper quadrant pain or tenderness, fever, rash, 
and/or eosinophilia (>5%)   
Source: FDA 2009 and other consensus guidelines, with minor modifications . 
Abbreviations: ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = asparta te aminotransferase; 
INR = international normalized ratio; TBL = total bilirubin level; ULN = upper limit of normal.  
Resuming study intervention  after elevated liver tests  
Resumption of the study intervention  can be considered only in consultation with the  
Lilly -designated medical monitor and only if the liver test results return to baseline and if a 
self-limited , non-drug etiology is identified. Otherwise, the study intervention  should be 
discontinued.  
Approved on [ADDRESS_629897] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
25 7.1.2.  Hypersensitivity  
If the investigator determines that a systemic hypersensitivity reaction has occurred related to 
study intervention administration, the participant may be permanently discontinued from the 
study intervention, and the sponsor’s designated medical monitor should be notified. If the 
investigato r is uncertain about whether a systemic hypersensitivity reaction has occurred and 
whether discontinuation of study intervention is warranted, the investigator may consult the 
sponsor.  
For laboratory samples to be obtained at the time of a systemic hyperse nsitivity event, see 
Section 10.2.1 .  
7.2. Participant Discontinuation/ Withdrawal from the Study  
See Master Protocol CPMP.  
7.3. Lost to Follow -Up 
See Master Protocol CPMP.  
Approved on [ADDRESS_629898] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
26 8. Study Assessments and Procedures  
Study procedures and their timing are summarized in Master Protocol  CPMP , DPNP CPMP(3) 
DSA, and ISA NP05 SoAs.  
LY3857210 -specific assessments and procedures are described here.  
8.1. Efficacy Assessments  
Planned time points for all efficacy assessments are provided in the SoAs.  
See Master Protocol CPMP and DSA CPMP(3) for additional information on efficacy 
assessments.  
8.2. Safety Assessments  
Planned time points for all efficacy assessments are provided in the SoAs.  
See Master Protocol CPMP and DSA CPMP(3) for additional information on safety asse ssments. 
Additional Study NP05 -specific assessment information is provided below.  
8.2.1.  Physical Examinations  
Complete physical examination , including targeted examination  specified below, should be 
performed at V3 and Visit [ADDRESS_629899], mammary gland in males , and lymph nodes will also be performed at Visits V5  and V7 as 
described in the SoA. Any clinically significant abnormal physical examination findings will be 
reported as AEs.  
In addition , a directed neurological assessment  will be performed by [CONTACT_093] (or 
designee) at the time points specified in the SoA. If abnormalities are noted at these time points, 
additional examinations should be performed as clinically necessary. The exam iner should be 
familiar with the participant’s baseline examination.  
Elements of the neurological assessment  include inspection for tremor, extraocular movements, 
brachial and patellar deep tendon reflexes, finger -nose pointing, and Romberg sign.   
8.2.2.  Electr ocardiograms  
Singl e 12-lead ECG will be obtained as outlined in the SoA (see Section  1.3) using an ECG 
machine that automatically calculates the heart rate and measures PR, RR, QRS, QT, and QTc F 
intervals. Refer to Section 7.[ADDRESS_629900] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
27 8.2.3.  Clinical Safety Laboratory Tests  
See NP05 Section 10.2 (Appendix 2) for the list of clinical laboratory tests to be performed and 
to the SoA for the timing and frequency for ISA NP05.  
Additional details are provided in the Master Protocol CPMP.  
8.3. Adverse Events , Serious Adverse Events , and Product Complaints  
The definitions of the following events can be found in Appendix 3  of Master Protocol CPMP : 
 AEs 
 SAEs , and  
 PCs. 
See Master Protocol CPMP Section 8.3 for additional details.  
8.3.1.  Pregnancy  
Collection of pregnancy information  
Male participants with partners who become pregnant  
● The investigator will attempt to collect pregnancy information on any male 
participant’s female partner who becomes pregnant while the male participant is 
in this study. This ap plies only to male participants who receive  study 
intervention . 
● After learning of a pregnancy in the female partner of a study participant, the 
investigator  
o will obtain a consent  to release information  from the pregnant female partner 
directly, and 
o within [ADDRESS_629901] pregnancy information 
on the appropriate form and submit it to the sponsor.  
The female partner will also be followed to determine the outcome of the 
pregnancy. Information on the status of the mothe r and child will be forwarded to 
the sponsor. Generally, the follow -up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any termination of the pregnancy will be 
reported regardless of gestational age,  fetal status (presence or abs ence of 
anomalies) , or indication for the procedure.  
Female participants who become pregnant  
● The investigator will collect pregnancy information on any female participant 
who becomes pregnant while participating in this study. The initial information 
will be recorded on the appropriate form and submitted to the sponsor within 24 
hours of learning of a participant's pregnancy.  
Approved on [ADDRESS_629902] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
28 ● The participant will be followed to determine the outcome of the pregnancy. The 
investigator will collect follow -up information on the participant and the neonate , 
and the information will be forwarded to the sponsor. Generally, follow -up will 
not be required for longer than 6 to 8 weeks beyond the estimated delivery date. 
Any termination of pregnancy will be reported, regardless o f gestational age,  fetal 
status (presence or absence of anomalies) , or indication for the procedure.  
● While pregnancy itself is not considered to be an AE or SAE, any pregnancy 
complication or elective termination of a pregnancy for medical reasons will b e 
reported as an AE or SAE.  
● A spontaneous abortion , occurring at <20 weeks gestational age , or still birth , 
occurring at ≥20 weeks gestational age , is always considered to be an SAE and 
will be reported as such.  
● Any post -study pregnancy -related SAE c onsidered reasonably related to the study 
intervention by [CONTACT_489929]  8.3.1 . While the investigator is not obligated to actively 
seek this information in former study participants , they may learn of an SAE 
through spontaneous reporting.  
● Any female participant who becomes pregnant while participating in the study 
will discontinue study intervention  and continue directly to the follow -up phase. 
The follow -up on the pregnancy outcome should continue independent of 
intervention or study discontinuation .   
8.3.2.  Hypersensitivity Reactions  
Many drugs, including oral agents and biologic agents, carry the risk of systemic hypersensitivity 
reactions. If such a reaction occurs, additional data should be provided to the sponsor in the 
designated CRFs.  
Sites should have appropriately trained medical staff and appropriate medical equipment 
available when study participants are receiving study intervention. It is recommended that 
participants w ho experience a systemic hypersensitivity reaction be treated per national and 
international guidelines.  
In the case of a suspected systemic hypersensitivity event, additional blood samples should be 
collected as described in Section  10.2.[ADDRESS_629903] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629904] es 
may be altered during the course of the study based on newly available data  to ensure appro priate 
data collection . 
Instructions for the collection and handling of PK samples will be provided by [CONTACT_456] . 
The date and time (24 -hour clock time) will be recorded for   
 LY3857210 administration prior to the PK sampl e collection , and   
 PK sample collection . 
PK samples  may also be used to evaluate safety or efficacy measures  related to concerns arising 
during or after the study   
8.5. Pharmacodynamics  
Pharmacodynamic assessments will not be evaluated in this study . 
Approved on [ADDRESS_629905] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
30 9. Statistical Considerations  
Master Protocol CPMP and DPNP DSA CPMP(3) provide statistical considerations. 
LY3857210 -specific considerations are described here.  
9.1. Statistical  Hypotheses  
Master Protocol CPMP describes the primary hypothesis.  
 
  
9.2. Analyses  Sets 
The populations are defined in Master Protocol  CPMP .  
The PK population includes all randomly assigned  participants who received a dose of 
LY3857210 and have at least [ADDRESS_629906] information will be specified in the ISA SAP. 
Secondary and tertiary  or exploratory endpoints and analyses are described in Master Protocol  
CPMP and DPNP DSA CPMP(3).  
Hand ling of missing, unused, and spurious data is addressed prospectively in the overall 
statistical methods described in the protocol and in the SAP, where appropriate. Adjustments to 
the planned analyses are described in the final CSR.  
9.3.2.  Tertiary  Analysis  
Expl oratory analyses may be described in the ISA SAP.  
9.3.3.  Safety Analyse s 
Safety analyses have been described in Master Protocol  CPMP. Additional ISA -specific safety 
analyses may be described in the ISA SAP.  
Approved on [ADDRESS_629907] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629908] anning.  Unblinding details 
would be specified in the unblinding plan section of the SAP or in a separate unblinding 
document. The SAP will describe any interim analyses in greater detail should they occur.  
9.5. Sample Size Determination  
Up to approximately 125  participants will be randomly assigned  to LY3857210  and placebo. It is 
expected that approximately 80% of participants will complete the double -blind treatment period 
of the study.
 
  
 
 If there is no treatment 
difference between placebo and LY3857210 , the probability of meeting the primary objective  
specified above ( that is , false positive) is approximately 0.[ADDRESS_629909] 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
32 10. Supporting Document ation and Operational Considerations  
10.1. Appendix 1: Regulatory, Ethical, and Study Oversight 
Considerations  
See Master Protocol CPMP for regulatory, ethical, and study oversight considerations.  
  
Approved on [ADDRESS_629910] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
33 10.2. Appendix 2: Clinical Laboratory Tests  
Master Protocol CPMP desc ribes tests that may be performed at additional times noted in the 
SoA for this ISA. This table describes tests unique for ISA NP05.  
Other Tests  Assayed by [CONTACT_11007] -designated laboratory .  
LY3857210 concentration   
Results will not be provided to the investigative sites . 
10.2.1.  Laboratory Samples to be Obtained at the Time of a Systemic Hypersensitivity 
Event  
Purpose of collecting samples after a systemic hypersensitivity event  
The samples listed in this appendix are not collected for acute study participant management. 
The sponsor will use the laboratory tests results from these samples to characterize 
hypersensitivity events across the clinical development program.  
When to coll ect samples after a systemic hypersensitivity event occurs  
Collect the samples listed below if a systemic hypersensitivity event is suspected. The timing 
should be as designated in the table, assuming the participant has been stabilized.  
Obtain follow -up predose samples at the next regularly scheduled laboratory sample collection 
(ideally prior to the next dose after the event) to assess post -event return -to-baseline values.  
Timing  Laboratory Test a 
Collect from 30 minutes to 4 hours after the start of 
the event.  
● Note: The optimal collection time is from 1 to 2 
hours after the start of event.  total tryptase  
complements ( C3, C3a, and C5a)  
cytokine panel ( IL-6, IL‐1β, IL‐10 , or any cytokine 
panel that includes these 3 cytokines)  
Abbreviation: IL = interleukin.  
a All samples for hypersensitivity testing will be assayed by [CONTACT_11007] -designated laboratory. Results will not be 
provided to the study site. If samples are not collected or are collected outside the specified time period, this will 
not be considered a protocol deviation.  
What information to record  
Record the date and time when the samples are collected.  
Allowed additional testing for participant management  
Approved on [ADDRESS_629911] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629912] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
35 10.3. Appendix 3: Adverse Events  and Serious Adverse Events : Definitions 
and Procedures for Recording, Evaluating, Follow -up, and 
Reporting  
See Master Protocol Appendix [ADDRESS_629913] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
36 10.4. Appendix 4: Contraceptive and Barrier Guidance  
10.4.1.  Definitions  
Word/Phrase  Definition  
Women of 
childbearing 
potential (WOCBP)  Adult females are considered WOCBP unless they are WNOCBP . 
Women not of 
childbearing 
potential 
(WNOCBP)  Females are considered WNOCBP  if they  
 have a congenital anomaly such as Müllerian agenesis  
 are infertile due to surgical sterilization, or  
 are postmenopausal.  
Examples of surgical sterilization include total hystere ctomy, bilateral 
salpi[INVESTIGATOR_8936] -oophorectomy, bilateral salpi[INVESTIGATOR_1656], or bilateral 
oophorectomy.  
Postmenopausal 
state The postmenopausal state is defined as a woman:  
 at any age at least [ADDRESS_629914] -surgical bilateral oophorectomy 
with or without hysterectomy, confirmed by [CONTACT_31083]; or  
 aged at least [ADDRESS_629915] 12 consecutive months without an alternative medical cause, 
AND with a follicle -stimulating hormone >40 mIU/mL; or  
 [ADDRESS_629916] 12 
months of spontaneous amenorrhea, or  
 aged at least 55 years with a diagnosis of menopause prior to 
starting hormone replacement therapy.  
a Women should not be taking medications during amenorrhea such as 
oral contraceptives, hormones, gonadotropin -releasing hormone, anti -
estrogens, Selective estrogen receptor modulators  (SERMs ), or 
chemotherapy that could induce transient amenorrhea.  
Approved on [ADDRESS_629917] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
37 10.4.2.  Contraception Guidance  
WOCBP who are completely abstinent as their preferred and usual lifestyle, or in a same -sex 
relationship as their preferred and usual lifestyle:  
Must…  Must not…  
agree to either remain abstinent or stay 
in a same -sex relationship without 
sexual relationships with males   use periodic abstinence methods  
o calendar  
o ovulation  
o symptothermal, or  
o post-ovulation  
 declare abstinence just for the duration of a trial, 
or 
 use the wit hdrawal method  
 
WOCBP who are NOT completely abstinent as their preferred and usual lifestyle, or NOT in a 
same -sex relationship as their preferred and usual lifestyle, must do the following:  
Topic  Condition  
Pregnancy testing  Have a negative serum test result at screening followed by a negative 
urine  result within [ADDRESS_629918] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
38 Examples of different forms of contraception:  
Methods  Examples  
Highly effective 
contraception (less than 
1% failure rate)   female sterilization  
 combination oral contraceptive pi[INVESTIGATOR_4382]  
 progestin -only contraceptive pi[INVESTIGATOR_4382] (mini -pi[INVESTIGATOR_4382]) 
 implanted contraceptives  
 injectable contraceptives  
 contraceptive patch (only women <198 pounds or 90 kg)  
 total abstinence  
 vasectomy (if only sexual partner)  
 fallopi[INVESTIGATOR_31077] (if confirmed by [CONTACT_31084][INVESTIGATOR_8913])  
 combined contraceptive vaginal ring, or  
 intrauterine devices  
Effective contraception   male or female condoms with spermicide  
 diaphragms with spermicide or cervical sponges  
 barrier method with use of a spermicide  
o condom with spermicide  
o diaphragm with spermicide, or  
o female condom with spermicide  
Ineffective forms of 
contraception whether 
used alone or in any 
combination   spermicide alone  
 periodic  abstinence  
 fertility awareness (calendar method, temperature method, 
cervical mucus, or symptothermal)  
 withdrawal  
 postcoital douche, or  
 lactational amenorrhea  
 
 
  
Approved on [ADDRESS_629919] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
39 10.5. Appendix 5: Liver Safety: Suggested Actions and Follow -up 
Assessments  
See Master Protocol CPMP  Appendix 6  for liver safety: suggested actions and follow -up 
assessments.  
  
Approved on [ADDRESS_629920] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
40 10.6. Appendix 6: Provisions for Changes in Study Conduct During 
Exceptional Circumstances  
Implementation of this appendix  
The changes to procedures described in this appendix are temporary measures intended to be 
used only during specific time periods as directed by [CONTACT_52019].  
Exceptional circumstances  
Exceptional circumstances are rare events  that may cause disruptions to the conduct of the s tudy. 
Examples include pandemics or natural disasters. These disruptions may limit the ability of the 
investigators, participants, or both to attend on -site visits or to conduct planned study procedures.  
Implementing changes under exceptional circumstances  
In an exceptional circumstance, after receiving the sponsor’s written approval, sites may 
implement changes if permitted by [CONTACT_427].  
After approval by [CONTACT_31086], regulatory bodies and any other relevant local 
authorities, impl ementation of these exceptional circumstance changes will not typi[INVESTIGATOR_51960], unless they have specific requirements in which 
notification is required (for example, upon implementation and suspension of changes). All 
approvals and notifications must be retained in the study records.  
If the sponsor grants written approval for changes in study conduct, the sponsor will also provide 
additional written guidance, if needed.  
Considerations for making a change  
The prevail ing consideration for making a change is ensuring the safety of study participants. 
Additional important considerations for making a change are compliance with Good Clinical 
Practice, enabling participants to continue safely in the study and maintaining th e integrity of the 
study.  
Informed consent  
Additional consent from the participant will be obtained, if required, for:  
 participation in remote visits, as defined in Section “Remote Visits”  
 dispensation of additional study intervention during an extended treatment period  
 alternate delivery of study intervention and ancillary supplies, and  
 provision of their personal or medical information required prior to implementation of 
these activities.   
Changes in study conduct during exceptional circumstances  
Changes in study conduct not described in this appendix, or not consistent with applicable local 
regulations, are not allowed.  
The following changes in study conduct will not be considered protoco l deviations.  
Approved on [ADDRESS_629921] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
41 Remote visits  
Telemedicine:  Telephone or technology -assisted virtual visits, or both, are acceptable to 
complete appropriate assessments.  
Mobile healthcare:  Healthcare visits may be performed by a mobile healthcare provider 
at locations other than the study site when participants cannot travel to the site due to an 
exceptional circumstance if written approval is provided by [CONTACT_456] .  
Procedures performed at such visits include, but are not limited to, collection of blood 
samples, symptom -directed physical examinations, ECGs, vital signs, intervention 
accountability and compliance, AE collection, and collection of health information.  
Other alternative locat ions:  Laboratory draws may be done at an alternate location in 
exceptional circumstances.  
In source documents and the CRF, the study site should capture the visit method, with a specific 
explanation for any data missing because of missed in -person site vi sits. 
Regardless of the type of remote visits implemented, the protocol requirements regarding the 
reporting of AEs, SAEs, and PCs remain unchanged.  
Every effort should be made to enable participants to return to on -site visits as soon as 
reasonably possi ble, while ensuring the safety of both the participants and the site staff.  
Local laboratory testing option  
Local laboratory testing may be conducted in lieu of central laboratory testing. The local 
laboratory must be qualified in accordance with applicabl e local regulations.  
 
Study intervention and ancillary supplies (including participant diaries)  
When a  participant is unable to go to the site to receive study supplies during normal on -site 
visits, the site should work with the sponsor to determine appropriate actions. These actions may 
include:  
 asking the participant to go to the site and receive study s upplies from site staff 
without completion of a full study visit  
 asking the participant’s designee to go to the site and receive study supplies on a 
participant’s behalf, and  
 arranging delivery of study supplies.  
These requirements must be met before acti on is taken:  
 Alternate delivery of study intervention should be performed in a manner that does 
not compromise treatment blinding and ensures product integrity. The existing 
protocol requirements for product accountability remain unchanged, including 
verif ication of participant’s receipt of study supplies.  
Approved on [ADDRESS_629922] 2022 GMT
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
42  When delivering supplies to a location other than the study site (for example, 
participant’s home), the investigator, sponsor, or both should ensure oversight of the 
shippi[INVESTIGATOR_489922] (that is, storage 
conditions maintained and intact packaging upon receipt).  
 Instructions may be provided to the participant or designee on the final disposition of 
any unused or completed study supplies . 
Adjustments to visit windows   
Whenever possible and safe to do so, as determined by [CONTACT_093]’s discretion, participants 
should complete the usual Schedule of Activities as described in Master Protocol  CPMP , 
CPMP(3) DSA, and NP05 ISA. To maximize the possibility that these vi sits can be conducted as 
on-site visits, the windows for visits may be adjusted, upon further guidance from the sponsor. 
This minimizes missing data and preserves the intended conduct of the study.  
For participants whose visits have extended windows, addi tional study intervention may need to 
be provided to avoid interruption and maintain overall integrity of the study.   
Documentation  
Sites will identify and document the details of how participants, visit types, and conducted 
activities were affected by [CONTACT_489930]. Dispensing/shipment records of study 
intervention and relevant communications, including delegation, should be filed with site study 
records.  
Source documents generated at a location other than the study site should be part of the 
investigator’s  source documentation and should be transferred to the site in a secure and timely 
manner.  
  
Approved on [ADDRESS_629923] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
43 10.7. Appendix 7: Abbreviations  and Definitions  
Term  Definition  
AE adverse event  
ALT alanine aminotransferase  
AUC  area under the curve  
AST aspartate aminotransferase  
CNS  central nervous system  
CPMP  chronic pain master protocol  
CRF case report form; a printed, optical, or electronic document designed to record all of the 
protocol -required information to be reported to the sponsor for each trial participant.  
DPNP  diabetic peripheral neuropathic pain  
DSA  disease -state appendix  
ECG  electrocardiogram  
ED early discontinuation  
eGFR  estimated glomerular filtration rate  
IB Investigator’s Brochure  
ISA intervention -specific appendix  
interim analysis  An interim analysis is an analysis of clinical study data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked.  
MAD  multiple -ascending dose  
MoO  Manual of Operations  
NRS  numeric rating scale  
participant  Equivalent to CDISC term “subject”: an individual who participates in a clinical trial, 
either as recipi[INVESTIGATOR_10930] a control  
PC product complaint  
PK pharmacokinetics  
POC  proof-of-concept  
Approved on [ADDRESS_629924] 2022 GMT
CCI
CCI
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629925] 2022 GMT
CONFIDENTIAL  Protocol  number  H0P-MC-NP05  (a) 
[ADDRESS_629926] on the 
activation of presynaptic AMPA receptors in rat trigeminal caudal nucleus glutamatergic nerve 
terminals. J Headache Pain . 2020;21(1):83. https://doi.org/ 10.1186/s10194 -020-[ZIP_CODE] -y 
[FDA] Food and Drug Administration. Guidance for Industry. Drug -Induced Liver Injury: 
Premarketing Clinical Evaluation , July 2009. Accessed August 2022. 
https://www.fda.gov/regulatory -information/search -fda-guidance -documents/dru g-induced -
liver-injury -premarketing -clinical -evaluation  
Zhang WJ, Zhu ZM, Liu ZX. The role and pharmacological properties of the P2X7 receptor in 
neuropathic pain. Brain Res Bull . 2020;155:19 -28. 
https://doi.org/10.1016/j.brainresbull.2019.11.[ADDRESS_629927]-2022 20:15:32 GMT[PHONE_006]
Approval
Medical Director
13-Oct-2022 23:04:08 GMT[PHONE_006]
Approved on [ADDRESS_629928] 2022 GMT
[COMPANY_003]
[COMPANY_003]